|
|
|
|
| LEADER |
02087nam a2200289 u 4500 |
| 001 |
EB002071986 |
| 003 |
EBX01000000000000001212076 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220923 r ||| eng |
| 020 |
|
|
|a 0309092140
|
| 020 |
|
|
|a 9780309092142
|
| 100 |
1 |
|
|a March, Andrew
|
| 245 |
0 |
0 |
|a Innovation in drug research and development for prevalent chronic diseases
|h Elektronische Ressource
|b proceedings of a workshop
|c Andrew March, Amanda Wagner Gee, Robert Pool, and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, and Medicine
|
| 260 |
|
|
|a Washington, DC
|b The National Academies Press
|c 2021, [2021]
|
| 300 |
|
|
|a 1 PDF file (xv, 96 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Gee, Amanda Wagner
|e [rapporteur]
|
| 700 |
1 |
|
|a Shore, Carolyn
|e [rapporteur]
|
| 700 |
1 |
|
|a Pool, Robert
|e [rapporteur]
|
| 710 |
2 |
|
|a National Academies of Sciences, Engineering, and Medicine (U.S.)
|b Forum on Drug Discovery, Development, and Translation
|
| 710 |
2 |
|
|a Innovation in Drug Research and Development for Prevalent Chronic Diseases (2021, Online)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK574242
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases
|